January 5, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Chimerix Inc (NASDAQ:CMRX) shares over potential securities laws violations by Chimerix and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Chimerix Inc (NASDAQ:CMRX) concerning whether a series of statements by Chimerix Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Chimerix, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. Shares of Chimerix Inc (NASDAQ:CMRX) grew from $15.40 per share in May 2014 to as high as $53.74 per share in July 2015.

On December 28, 2015, Chimerix Inc (NASDAQ:CMRX) announced that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection through Week 24 after transplant. Shares of Chimerix Inc (NASDAQ:CMRX) declined from $35.82 per share on December 24, 2015, to as low as $6.51 per share on December 28, 2015.